Tesevatinib
Tesevatinib ARPKD Useful in Animal Studies
Tesevatinib ADPKD still in clinical trials
Tesevatinib is tyrosine kinase inhibitor for the treatment of polycystic kidney disease. Tesevatinib is well tolerated and can be taken once a day tesevatinib 50 mg as the optimal dose to treat ADPKD. At UCLA in the US, clinical trials for ADPKD will be tried. It increases serum creatinine (not usually a good thing in PKD), but while taking Tesevatinib this was thought to not effect PKD kidney functioning. New data demonstrated that serum creatinine levels in tesevatinib patients increased by 10% to 14% during the first 28 days of treatment and reversed upon treatment discontinuation. Importantly, levels of cystatin C, another measure of renal function, were relatively unchanged during the same period.MATE 1/2-K inhibitors (Tesevatinib), this increases serum creatinine which occurs without clinically meaningful alterations in renal function.